Gene, Cell and Tissue

Published by: Kowsar

Critical Roles of Non-coding RNAs in Acute Lymphoblastic Leukemia

Maryam Mazloumi Gavgani 1 , Mansooreh Nargesian 2 and Saeid Ghorbian 1 , *
Authors Information
1 Department of Molecular Genetics, Ahar Branch, Islamic Azad University, Ahar, Iran
2 Young Researchers and Elite Club, Ahar Branch, Islamic Azad University, Ahar, Iran
Article information
  • Gene, Cell and Tissue: 5 (4); e83297
  • Published Online: December 26, 2018
  • Article Type: Review Article
  • Received: August 13, 2018
  • Revised: December 20, 2018
  • Accepted: December 23, 2018
  • DOI: 10.5812/gct.83297

To Cite: Mazloumi Gavgani M, Nargesian M , Ghorbian S. Critical Roles of Non-coding RNAs in Acute Lymphoblastic Leukemia, Gene Cell Tissue. Online ahead of Print ; 5(4):e83297. doi: 10.5812/gct.83297.

Abstract
Copyright © 2018, Gene, Cell and Tissue. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Introduction
2. Micro-RNA Biogenesis and Functions
3. Deregulation of miRNAs in ALL
4. Conclusions
Footnotes
References
  • 1. Ambros V. MicroRNA pathways in flies and worms: Growth, death, fat, stress, and timing. Cell. 2003;113(6):673-6. [PubMed: 12809598].
  • 2. Kian R, Moradi S, Ghorbian S. Role of components of microRNA machinery in carcinogenesis. Exp Oncol. 2018;40(1):2-9. [PubMed: 29600985].
  • 3. Palatnik JF, Allen E, Wu X, Schommer C, Schwab R, Carrington JC, et al. Control of leaf morphogenesis by microRNAs. Nature. 2003;425(6955):257-63. doi: 10.1038/nature01958. [PubMed: 12931144].
  • 4. Garitano-Trojaola A, Agirre X, Prosper F, Fortes P. Long non-coding RNAs in haematological malignancies. Int J Mol Sci. 2013;14(8):15386-422. doi: 10.3390/ijms140815386. [PubMed: 23887658]. [PubMed Central: PMC3759866].
  • 5. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75(5):843-54. [PubMed: 8252621].
  • 6. Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell. 1993;75(5):855-62. [PubMed: 8252622].
  • 7. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281-97. [PubMed: 14744438].
  • 8. Bartel DP. MicroRNAs: Target recognition and regulatory functions. Cell. 2009;136(2):215-33. doi: 10.1016/j.cell.2009.01.002. [PubMed: 19167326]. [PubMed Central: PMC3794896].
  • 9. He C, Luo B, Jiang N, Liang Y, He Y, Zeng J, et al. OncomiR or antioncomiR: Role of miRNAs in acute myeloid leukemia. Leuk Lymphoma. 2018:1-12. doi: 10.1080/10428194.2018.1480769. [PubMed: 30187809].
  • 10. Fulci V, Colombo T, Chiaretti S, Messina M, Citarella F, Tavolaro S, et al. Characterization of B- and T-lineage acute lymphoblastic leukemia by integrated analysis of MicroRNA and mRNA expression profiles. Genes Chromosomes Cancer. 2009;48(12):1069-82. doi: 10.1002/gcc.20709. [PubMed: 19760605].
  • 11. Shenouda SK, Alahari SK. MicroRNA function in cancer: Oncogene or a tumor suppressor? Cancer Metastasis Rev. 2009;28(3-4):369-78. doi: 10.1007/s10555-009-9188-5. [PubMed: 20012925].
  • 12. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009;10(10):704-14. doi: 10.1038/nrg2634. [PubMed: 19763153]. [PubMed Central: PMC3467096].
  • 13. Borchert GM, Lanier W, Davidson BL. RNA polymerase III transcribes human microRNAs. Nat Struct Mol Biol. 2006;13(12):1097-101. doi: 10.1038/nsmb1167. [PubMed: 17099701].
  • 14. Altuvia Y, Landgraf P, Lithwick G, Elefant N, Pfeffer S, Aravin A, et al. Clustering and conservation patterns of human microRNAs. Nucleic Acids Res. 2005;33(8):2697-706. doi: 10.1093/nar/gki567. [PubMed: 15891114]. [PubMed Central: PMC1110742].
  • 15. Hertel J, Lindemeyer M, Missal K, Fried C, Tanzer A, Flamm C, et al. The expansion of the metazoan microRNA repertoire. BMC Genomics. 2006;7(25). doi: 10.1186/1471-2164-7-25. [PubMed: 16480513]. [PubMed Central: PMC1388199].
  • 16. Yeom KH, Lee Y, Han J, Suh MR, Kim VN. Characterization of DGCR8/Pasha, the essential cofactor for Drosha in primary miRNA processing. Nucleic Acids Res. 2006;34(16):4622-9. doi: 10.1093/nar/gkl458. [PubMed: 16963499]. [PubMed Central: PMC1636349].
  • 17. Zeng Y. Principles of micro-RNA production and maturation. Oncogene. 2006;25(46):6156-62. doi: 10.1038/sj.onc.1209908. [PubMed: 17028594].
  • 18. Lee Y, Hur I, Park SY, Kim YK, Suh MR, Kim VN. The role of PACT in the RNA silencing pathway. EMBO J. 2006;25(3):522-32. doi: 10.1038/sj.emboj.7600942. [PubMed: 16424907]. [PubMed Central: PMC1383527].
  • 19. Khvorova A, Reynolds A, Jayasena SD. Functional siRNAs and miRNAs exhibit strand bias. Cell. 2003;115(2):209-16. [PubMed: 14567918].
  • 20. Vandenboom Ii TG, Li Y, Philip PA, Sarkar FH. MicroRNA and cancer: Tiny molecules with major implications. Curr Genomics. 2008;9(2):97-109. doi: 10.2174/138920208784139555. [PubMed: 19440450]. [PubMed Central: PMC2674802].
  • 21. Garofalo M, Croce CM. microRNAs: Master regulators as potential therapeutics in cancer. Annu Rev Pharmacol Toxicol. 2011;51:25-43. doi: 10.1146/annurev-pharmtox-010510-100517. [PubMed: 20809797].
  • 22. Medina PP, Slack FJ. microRNAs and cancer: An overview. Cell Cycle. 2008;7(16):2485-92. doi: 10.4161/cc.7.16.6453. [PubMed: 18719380].
  • 23. Palmero EI, de Campos SG, Campos M, de Souza NC, Guerreiro ID, Carvalho AL, et al. Mechanisms and role of microRNA deregulation in cancer onset and progression. Genet Mol Biol. 2011;34(3):363-70. doi: 10.1590/S1415-47572011000300001. [PubMed: 21931505]. [PubMed Central: PMC3168173].
  • 24. Mullighan CG. Molecular genetics of B-precursor acute lymphoblastic leukemia. J Clin Invest. 2012;122(10):3407-15. doi: 10.1172/JCI61203. [PubMed: 23023711]. [PubMed Central: PMC3461902].
  • 25. Fernando TR, Rodriguez-Malave NI, Waters EV, Yan W, Casero D, Basso G, et al. LncRNA expression discriminates karyotype and predicts survival in B-lymphoblastic leukemia. Mol Cancer Res. 2015;13(5):839-51. doi: 10.1158/1541-7786.MCR-15-0006-T. [PubMed: 25681502]. [PubMed Central: PMC4433429].
  • 26. Aalijahan H, Ghorbian S. Long non-coding RNAs and cervical cancer. Exp Mol Pathol. 2018;106:7-16. doi: 10.1016/j.yexmp.2018.11.010. [PubMed: 30471246].
  • 27. Bousquet M, Broccardo C, Quelen C, Meggetto F, Kuhlein E, Delsol G, et al. A novel PAX5-ELN fusion protein identified in B-cell acute lymphoblastic leukemia acts as a dominant negative on wild-type PAX5. Blood. 2007;109(8):3417-23. doi: 10.1182/blood-2006-05-025221. [PubMed: 17179230].
  • 28. Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature. 2008;453(7191):110-4. doi: 10.1038/nature06866. [PubMed: 18408710].
  • 29. Mullighan CG, Su X, Zhang J, Radtke I, Phillips LA, Miller CB, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009;360(5):470-80. doi: 10.1056/NEJMoa0808253. [PubMed: 19129520]. [PubMed Central: PMC2674612].
  • 30. Coyaud E, Struski S, Prade N, Familiades J, Eichner R, Quelen C, et al. Wide diversity of PAX5 alterations in B-ALL: A groupe francophone de cytogenetique hematologique study. Blood. 2010;115(15):3089-97. doi: 10.1182/blood-2009-07-234229. [PubMed: 20160164].
  • 31. Medina PP, Nolde M, Slack FJ. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature. 2010;467(7311):86-90. doi: 10.1038/nature09284. [PubMed: 20693987].
  • 32. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354(2):166-78. doi: 10.1056/NEJMra052603. [PubMed: 16407512].
  • 33. Tanzer A, Stadler PF. Molecular evolution of a microRNA cluster. J Mol Biol. 2004;339(2):327-35. doi: 10.1016/j.jmb.2004.03.065. [PubMed: 15136036].
  • 34. Ventura A, Young AG, Winslow MM, Lintault L, Meissner A, Erkeland SJ, et al. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell. 2008;132(5):875-86. doi: 10.1016/j.cell.2008.02.019. [PubMed: 18329372]. [PubMed Central: PMC2323338].
  • 35. Thomson JM, Parker J, Perou CM, Hammond SM. A custom microarray platform for analysis of microRNA gene expression. Nat Methods. 2004;1(1):47-53. doi: 10.1038/nmeth704. [PubMed: 15782152].
  • 36. Houbaviy HB, Murray MF, Sharp PA. Embryonic stem cell-specific MicroRNAs. Dev Cell. 2003;5(2):351-8. [PubMed: 12919684].
  • 37. Suh MR, Lee Y, Kim JY, Kim SK, Moon SH, Lee JY, et al. Human embryonic stem cells express a unique set of microRNAs. Dev Biol. 2004;270(2):488-98. doi: 10.1016/j.ydbio.2004.02.019. [PubMed: 15183728].
  • 38. Obernosterer G, Leuschner PJ, Alenius M, Martinez J. Post-transcriptional regulation of microRNA expression. RNA. 2006;12(7):1161-7. doi: 10.1261/rna.2322506. [PubMed: 16738409]. [PubMed Central: PMC1484437].
  • 39. Wulczyn FG, Smirnova L, Rybak A, Brandt C, Kwidzinski E, Ninnemann O, et al. Post-transcriptional regulation of the let-7 microRNA during neural cell specification. FASEB J. 2007;21(2):415-26. doi: 10.1096/fj.06-6130com. [PubMed: 17167072].
  • 40. Thomson JM, Newman M, Parker JS, Morin-Kensicki EM, Wright T, Hammond SM. Extensive post-transcriptional regulation of microRNAs and its implications for cancer. Genes Dev. 2006;20(16):2202-7. doi: 10.1101/gad.1444406. [PubMed: 16882971]. [PubMed Central: PMC1553203].
  • 41. Scherr M, Elder A, Battmer K, Barzan D, Bomken S, Ricke-Hoch M, et al. Differential expression of miR-17~92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia. Leukemia. 2014;28(3):554-65. doi: 10.1038/leu.2013.361. [PubMed: 24280866]. [PubMed Central: PMC3948162].
  • 42. Mu P, Han YC, Betel D, Yao E, Squatrito M, Ogrodowski P, et al. Genetic dissection of the miR-17~92 cluster of microRNAs in Myc-induced B-cell lymphomas. Genes Dev. 2009;23(24):2806-11. doi: 10.1101/gad.1872909. [PubMed: 20008931]. [PubMed Central: PMC2800095].
  • 43. Olive V, Bennett MJ, Walker JC, Ma C, Jiang I, Cordon-Cardo C, et al. miR-19 is a key oncogenic component of mir-17-92. Genes Dev. 2009;23(24):2839-49. doi: 10.1101/gad.1861409. [PubMed: 20008935]. [PubMed Central: PMC2800084].
  • 44. Xiao C, Srinivasan L, Calado DP, Patterson HC, Zhang B, Wang J, et al. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol. 2008;9(4):405-14. doi: 10.1038/ni1575. [PubMed: 18327259]. [PubMed Central: PMC2533767].
  • 45. Cory S, Huang DC, Adams JM. The Bcl-2 family: Roles in cell survival and oncogenesis. Oncogene. 2003;22(53):8590-607. doi: 10.1038/sj.onc.1207102. [PubMed: 14634621].
  • 46. Strasser A. The role of BH3-only proteins in the immune system. Nat Rev Immunol. 2005;5(3):189-200. doi: 10.1038/nri1568. [PubMed: 15719025].
  • 47. Sanchez-Garcia I, Grutz G. Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2. Proc Natl Acad Sci U S A. 1995;92(12):5287-91. [PubMed: 7777499]. [PubMed Central: PMC41679].
  • 48. Den Boer ML, Harms DO, Pieters R, Kazemier KM, Gobel U, Korholz D, et al. Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. J Clin Oncol. 2003;21(17):3262-8. doi: 10.1200/JCO.2003.11.031. [PubMed: 12947061].
  • 49. Hongo T, Yajima S, Sakurai M, Horikoshi Y, Hanada R. In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia. Blood. 1997;89(8):2959-65. [PubMed: 9108416].
  • 50. Kaspers GJ, Veerman AJ, Pieters R, Van Zantwijk CH, Smets LA, Van Wering ER, et al. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood. 1997;90(7):2723-9. [PubMed: 9326239].
  • 51. Wang W, Wang X, Zhang Y, Wang D, Gao H, Wang L, et al. Prognostic role of microRNA-150 in various carcinomas: A meta-analysis. Onco Targets Ther. 2016;9:1371-9. doi: 10.2147/OTT.S97969. [PubMed: 27042106]. [PubMed Central: PMC4795660].
  • 52. Xiao C, Calado DP, Galler G, Thai TH, Patterson HC, Wang J, et al. MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb. Cell. 2007;131(1):146-59. doi: 10.1016/j.cell.2007.07.021. [PubMed: 17923094].
  • 53. Zhou B, Wang S, Mayr C, Bartel DP, Lodish HF. miR-150, a microRNA expressed in mature B and T cells, blocks early B cell development when expressed prematurely. Proc Natl Acad Sci U S A. 2007;104(17):7080-5. doi: 10.1073/pnas.0702409104. [PubMed: 17438277]. [PubMed Central: PMC1855395].
  • 54. He Y, Jiang X, Chen J. The role of miR-150 in normal and malignant hematopoiesis. Oncogene. 2014;33(30):3887-93. doi: 10.1038/onc.2013.346. [PubMed: 23955084].
  • 55. Ghisi M, Corradin A, Basso K, Frasson C, Serafin V, Mukherjee S, et al. Modulation of microRNA expression in human T-cell development: Targeting of NOTCH3 by miR-150. Blood. 2011;117(26):7053-62. doi: 10.1182/blood-2010-12-326629. [PubMed: 21551231].
  • 56. Ranganath P. MicroRNA-155 and its role in malignant hematopoiesis. Biomark Insights. 2015;10:95-102. doi: 10.4137/BMI.S27676. [PubMed: 26523117]. [PubMed Central: PMC4620936].
  • 57. Huffaker TB, Hu R, Runtsch MC, Bake E, Chen X, Zhao J, et al. Epistasis between microRNAs 155 and 146a during T cell-mediated antitumor immunity. Cell Rep. 2012;2(6):1697-709. doi: 10.1016/j.celrep.2012.10.025. [PubMed: 23200854]. [PubMed Central: PMC3628775].
  • 58. Verduci L, Azzalin G, Gioiosa S, Carissimi C, Laudadio I, Fulci V, et al. microRNA-181a enhances cell proliferation in acute lymphoblastic leukemia by targeting EGR1. Leuk Res. 2015;39(4):479-85. doi: 10.1016/j.leukres.2015.01.010. [PubMed: 25740602].
  • 59. Lui WO, Pourmand N, Patterson BK, Fire A. Patterns of known and novel small RNAs in human cervical cancer. Cancer Res. 2007;67(13):6031-43. doi: 10.1158/0008-5472.CAN-06-0561. [PubMed: 17616659].
  • 60. Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A, et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell. 2007;129(7):1401-14. doi: 10.1016/j.cell.2007.04.040. [PubMed: 17604727]. [PubMed Central: PMC2681231].
  • 61. Monteleone NJ, Lutz CS. miR-708-5p: A microRNA with emerging roles in cancer. Oncotarget. 2017;8(41):71292-316. doi: 10.18632/oncotarget.19772. [PubMed: 29050362]. [PubMed Central: PMC5642637].
  • 62. Schotte D, Chau JC, Sylvester G, Liu G, Chen C, van der Velden VH, et al. Identification of new microRNA genes and aberrant microRNA profiles in childhood acute lymphoblastic leukemia. Leukemia. 2009;23(2):313-22. doi: 10.1038/leu.2008.286. [PubMed: 18923441].
  • 63. Pekarsky Y, Santanam U, Cimmino A, Palamarchuk A, Efanov A, Maximov V, et al. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res. 2006;66(24):11590-3. doi: 10.1158/0008-5472.CAN-06-3613. [PubMed: 17178851].
  • 64. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A. 2007;104(40):15805-10. doi: 10.1073/pnas.0707628104. [PubMed: 17890317]. [PubMed Central: PMC2000384].
  • 65. Gebeshuber CA, Zatloukal K, Martinez J. miR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis. EMBO Rep. 2009;10(4):400-5. doi: 10.1038/embor.2009.9. [PubMed: 19247375]. [PubMed Central: PMC2672883].
  • 66. Mazzoccoli L, Robaina MC, Apa AG, Bonamino M, Pinto LW, Queiroga E, et al. MiR-29 silencing modulates the expression of target genes related to proliferation, apoptosis and methylation in Burkitt lymphoma cells. J Cancer Res Clin Oncol. 2018;144(3):483-97. doi: 10.1007/s00432-017-2575-3. [PubMed: 29318382].
  • 67. Oliveira LH, Schiavinato JL, Fraguas MS, Lucena-Araujo AR, Haddad R, Araujo AG, et al. Potential roles of microRNA-29a in the molecular pathophysiology of T-cell acute lymphoblastic leukemia. Cancer Sci. 2015;106(10):1264-77. doi: 10.1111/cas.12766. [PubMed: 26251039]. [PubMed Central: PMC4637998].
  • 68. Tan Y, Ge G, Pan T, Wen D, Chen L, Yu X, et al. A serum microRNA panel as potential biomarkers for hepatocellular carcinoma related with hepatitis B virus. PLoS One. 2014;9(9). e107986. doi: 10.1371/journal.pone.0107986. [PubMed: 25238238]. [PubMed Central: PMC4169601].
  • 69. Sayadi M, Ajdary S, Nadali F, Rostami S, Edalati Fahtabad M. Tumor suppressive function of microRNA-192 in acute lymphoblastic leukemia. Bosn J Basic Med Sci. 2017;17(3):248-54. doi: 10.17305/bjbms.2017.1921. [PubMed: 28488550]. [PubMed Central: PMC5581974].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments